InsuletPODD
About: Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
Employees: 3,000
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
42% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 64
13% more capital invested
Capital invested by funds: $14.4B [Q2] → $16.4B (+$1.92B) [Q3]
3% more funds holding
Funds holding: 589 [Q2] → 609 (+20) [Q3]
5% less repeat investments, than reductions
Existing positions increased: 220 | Existing positions reduced: 232
1.46% less ownership
Funds ownership: 102.17% [Q2] → 100.72% (-1.46%) [Q3]
29% less call options, than puts
Call options by funds: $163M | Put options by funds: $229M
75% less funds holding in top 10
Funds holding in top 10: 8 [Q2] → 2 (-6) [Q3]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
TD Cowen Joshua Jennings 48% 1-year accuracy 10 / 21 met price target | 15%upside $324 | Buy Maintained | 3 Jan 2025 |
JP Morgan Robbie Marcus 65% 1-year accuracy 13 / 20 met price target | 18%upside $330 | Overweight Maintained | 12 Dec 2024 |
Citigroup Joanne Wuensch 66% 1-year accuracy 31 / 47 met price target | 10%upside $310 | Buy Maintained | 11 Dec 2024 |
Wells Fargo Lawrence Biegelsen 67% 1-year accuracy 2 / 3 met price target | 9%upside $305 | Overweight Maintained | 11 Dec 2024 |
Canaccord Genuity William Plovanic 71% 1-year accuracy 35 / 49 met price target | 8%upside $304 | Buy Maintained | 9 Dec 2024 |
Financial journalist opinion
Based on 3 articles about PODD published over the past 30 days









